227 results about "Pulmonary circulation diseases" patented technology

Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)). Additional aspects include therapeutic compositions, and combination treatment methods comprising administration of electrokinetically generated fluid in combination with at least one additional therapeutic agent.

The present invention encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1 / Edg1 receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the S1P1 / Edg1 receptor over the S1PR3 / Edg3 receptor, said compound administered in an amount effective for treating said immunoregulatory abnormality. Pharmaceutical compositions are included. The invention also encompasses a method of identifying candidate compounds that are agonists of the S1P1 / Edg1 receptor and which possesses a selectivity for the S1P1 / Edg1 receptor over the S1PR3 / Edg3 receptor. The invention further encompasses a method of treating a respiratory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1 / Edg1 receptor in an amount effective for treating said respiratory disease or condition, wherein said compound possesses a selectivity for the S1P1 / Edg1 receptor over the S1PR3 / Edg3 receptor.

Provided are compositions and methods for treating or preventing lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis (e.g. nose respiratory tract), and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically generated fluid (including gas-enriched electrokinetically generated fluids) as disclosed herein, the electrokinetically altered aqueous fluid suitable to alter cellular membrane structure or function sufficient to provide for modulation of intracellular signal transduction, wherein treating a lung disorder or a symptom thereof is thereby afforded. Additional aspects relate to therapeutic compositions, and combination treatment methods comprising administration of at least one electrokinetically generated fluid in combination with at least one additional therapeutic agent.

The present invention relates to pharmaceutical compositions for the sustained release of pharmacologically active compounds and methods of their manufacture and use. Sustained release times of 10-12 days have been achieved with the present invention. The present invention provides microcrystal compositions. The microcrystals comprise pharmacologically active compounds and are contained within a phospholipid layer which contains a unique combination of phospholipids. The present invention may be applied to a wide range of pharmaceutical compositions which may be rendered suitable for injection. The microcrystals are of varying sizes. At least 50 percent of the microcrystals are from 0.5 mum to about 3.0 mum in diameter, at least ten percent of the microcrystals are from about 3.0 mum to about 10 mum in diameter, and the composition contains microcrystals which are greater than 10 mum in diameter. In preferred embodiments, at least about 1% of the microcrystals are greater than 10 mum in diameter. The compositions and methods are useful for treating respiratory diseases, infections, inflammation, and pain in a variety of mammals. The compounds and methods are also able to sharply reduce the toxicity of drug compounds.

The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.

The invention discloses a Chinese medicinal herb additive for egg chickens and application. The Chinese medicinal herb additive comprises membranous milkvetch root, eucommia bark, honeysuckle, jiuyue, Weeping Forsythiae Capsule, szechwon tangshen root, sanguisorba, hawthorn, Indian Buead, officinal magnolia bark, Chinese pulsatilla root, giant knotweed rhizome, ricepaperplant pith, largehead atractylodes rhizome, tangerine peel, malt, indigowoad root, swordlike atractylodes rhizome, indigowoad leaf, three immortals, liquorice, cyrtomium fortune, nutgrass galingale rhizome, chatoyancy, calamus and pinellia tuber, and mixture of the compositions is added with calcium bicarbonate, phytase, vitamin E and methionine. The Chinese medicinal herb additive effectively promotes absorption of nutrient, can prevent and control diseases, strengthen quality of eggshells, reduce the broken egg rate and soft-shell eggs, abnormal eggs and sand shell eggs, can effectively prevent bird flu, prevent and control diseases such as laxness, feather pecking, hair shedding, anus pecking, salpingitis, respiratory disease and the like, can achieve good effect with a dosage of about 4 percent, cannot damage physiological functions of the egg chickens, and can prolong egg laying peak season, improve color of the eggshells and the laying rate by 8 to 20 percent, and increase weight of eggs.

The invention discloses an additive which can reduce harmful components in smoke and the preparation method. The invention is mainly characterized in that the materials include jasmine tea, liquorice, Beta-cyclodextrin, polyethylene glycol, honey, lactic acid and glyceryl triacetate and the materials are processed into cigarette filter additive, and then are evenly sprinkled on the polypropylene or acetate fiber cigarette filter rod and at last are rolled into a cigarette; the weight of the additive is 0.5-5% of the weight of the cigarette filter rod. Compared with a reference cigarette, the cigarette filter rod additive is balanced in tea aroma, flower fragrance, cigarette aroma and drug aroma and can improve the taste of the cigarette, enabling the cigarette to have balanced aroma, comfortable aftertaste and slender and soft smoke; the invention also reduces total particulate matter in the cigarette by 3.0-5.6%, tar by 2.9-6.6%, carbon monoxide by 2.5-10% and nicotinamide by 0.9-1%, and effectively reduces peppery irritation to the respiratory system of the smoker from the smoke, reduces respiratory diseases as well as harm to the smoker.

Combinations comprising (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.

Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

The invention discloses a Chinese medicinal herb additive for egg ducks and application thereof. The Chinese medicinal herb additive comprises amur corktree bark, eucommia bark, honeysuckle, szechwon tangshen root, sanguisorba, hawthorn, Indian Buead, officinal magnolia bark, Chinese pulsatilla root, giant knotweed rhizome, ricepaperplant pith, largehead atractylodes rhizome, tangerine peel, malt, indigowoad root, swordlike atractylodes rhizome, indigowoad leaf, three immortals, liquorice, cyrtomium fortune, nutgrass galingale rhizome, chatoyancy and calamus, and mixture of the compositions is added with calcium bicarbonate, phytase, vitamin E and methionine. The Chinese medicinal herb additive effectively promotes absorption of nutrient, can prevent and control diseases, strengthen quality of eggshells, reduce the broken egg rate and soft-shell eggs, abnormal eggs and sand shell eggs, can effectively prevent bird flu, prevent and control diseases such as laxness, feather pecking, hair shedding, anus pecking, salpingitis, respiratory disease and the like, can achieve good effect with a dosage of about 4 percent, cannot damage physiological functions of the egg ducks, and can prolong egg laying peak season, improve color of the eggshells and the laying rate by 9 to 20 percent, and increase weight of eggs.

The invention discloses an animal feed additive and a preparation method thereof. The animal feed additive is prepared from the following raw materials in parts by weight: 5-10 parts of corn fiber, 15-20 parts of soybean curb residue, 12-15 parts of zeolite powder, 40-60 parts of corn sugar residue, 1 part of compound biological active enzyme, 1 part of saccharomycetes, 1 part of lactobacillus, 1 part of bacillus and 1 part of bifidobacterium, wherein the compound biological active enzyme comprises the following components: 20,000 IU / g of xylanase, 10,000 IU / g of pectinase, 400 IU / g of cellulose and 200 IU / g of protease. The preparation method comprises the steps of raw material weighing, pre-processing, mixing, dual fermentation and packaging. The animal feed additive disclosed by the invention can be used for improving the digestibility to promote the growth and development of animals, regulating the gastrointestinal micro-ecological balance to enhance animal immunity and improve disease resistance, improving animal feed intake, improving the cultivation environment to reduce respiratory diseases, and improving the quality and quantity of cultivated products.

The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., Pd(II)-, Ni(II)-, or Fe(II)-ligand of Formula (A)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers Y. The provided supramolecular complexes are able to form gels (e.g., hydrogels). The gels are suprametallogels and exhibited excellent mechanical properties without sacrificing self-healing and showed high robustness and storage modulus. The present disclosure further provides compositions (e.g., gels) that include the nanostructures or supramolecular complexes and optionally an agent (e.g., small molecule), where the nanostructures and the nanostructure moieties of the supramolecular complexes may encapsulate and slowly release the agent. The nanostructures, supramolecular complex, and compositions may be useful in delivering an agent to a subject, tissue, or cell, as super-absorbent materials, and in treating a disease (e.g., a genetic diseases, proliferative disease (e.g., cancer or benign neoplasm), hematological disease, neurological disease, gastrointestinal disease (e.g., liver disease), spleen disease, respiratory disease (e.g., lung disease), painful condition, genitourinary disease, musculoskeletal condition, infectious disease, inflammatory disease, autoimmune disease, psychiatric disorder, or metabolic disorder).

It is an object of the present invention to provide an ejection liquid (liquid composition) which can be stably ejected as a liquid containing an effective ingredient for treating respiratory disease from an ejection opening provided to an ejection device. A specific surface-active compound is added to an ejection liquid containing an effective ingredient for treating respiratory disease. An ejection liquid which is used for stably ejecting a solution containing an active ingredient for treating respiratory disease according to the principle of an ink jet system, a method which is suitable for ejecting this ejection liquid, and an ejection device are provided. The ejection liquid includes an active ingredient for treating j respiratory disease, a specific surface-active compound, and a liquid medium and is ejected from an ejection opening by an ink jet system.

The present invention relates to the field of using fruits dregs to perform deep-processing technique, specifically to a deep-processing process of kiwi berry dregs. The present invention provides a deep-processing process of kiwi berry dregs for overcoming the problem existing in the prior art such as increased enterprise cost, environment pollution and kiwi berry resource waste. The technical program of the invention is deep-processing process of kiwi berry dregs including in sequence the following steps: first, kiwi berry dregs pretreatment; second, primary fermentation; third, a secondary fermentation; fourth, post-processing. The invention has advantages as follows: the produces kiwi berry fruit vinegar has a certain health care functions: promote appetite strengthen spleen, relieve smell dehumidification, the elimination of fatigue, lower blood pressure, increase appetite, promote digestion, protect skin, the treatment of colds and respiratory diseases.

The invention relates to the field of pharmaceutical preparations and particularly relates to a slow-release micropill preparation containing enrofloxacin and a preparation method of the preparation. The slow-release micropill provided by the invention is formed by coating an enrofloxacin micropill; the enrofloxacin micropill comprises enrofloxacin and auxiliary material and is formed through extruding and rounding; the auxiliary material is any one or more of microcrystalline cellulose, starch, cane sugar, artificial gum, lactose and sodium carboxymethyl starch; according to weight percent, the auxiliary material in the micropill accounts for 70% to 95%; and coating is made of high-molecular enteric material, film forming material, opaquer and the like. The slow-release micropill preparation has the characteristics of slow release and high bioavailability, can be used for treating bacteria and mycoplasma infection of livestocks, and has better curative effect on chronic respiratory diseases, colibacillosis and salmonellosis, and the frequency of medicine taking can be reduced; and in addition, the slow-release micropill provided by the invention has the advantages that the stability of medicine is improved, and peculiar bitter of enrofloxacin can be covered completely, so that feeding intake of the animals is not influenced, and the recovery rate is improved.

The invention belongs to the field of feed, and particularly relates to egg-laying duck feed. The feed comprises the following formula: 10-40 parts of husk, 40 - 80 parts of corn flour, 20 - 50 parts of peanut meal, 10 - 30 parts of soybean meal, 1 - 4 parts of calcium hydrogen phosphate, 5 - 15 parts of stone powder, 1 - 5 parts of salt, 5 - 20 parts of a premix, 1 - 5 parts of calcium carbonate, 5 - 15 parts of sesame meal, 5 - 20 parts of rapeseed meal, 1 - 4 parts of methionine, 2 - 8 parts of fish meal, 2 - 7 parts of plant extracts, 10 - 20 parts of cottonseed meal, 10 - 20 parts of sweet potato powder, 2 - 8 parts of choline, 2 - 7 parts of trace elements, 2 - 9 parts of vegetable oil, 1 - 5 parts of a complex enzyme preparation, 1 - 4 parts of amino acids and 1 - 4 parts of zinc sulfate. By feeding egg-laying ducks with the egg-laying duck feed containing the plant extracts, the feed can be saved, the feed dosage and feeding cost ate reduced, and duck raising benefits are improved; by feeding the egg-laying ducks with the egg-laying duck feed formula, the egg laying rate of the egg-laying ducks is high; the body's immunity is improved due to the medicinal functions of the plant extracts, the incidence of diseases is reduced, the use of drugs is reduced, and safe relieved animal by-product duck eggs cam be produced; and respiratory diseases, beak and anus diseases, beak and feather diseases and other phenomena of the ducks in a raising process can be reduced.

The invention relates to the technical field of tea leaf processing and in particular relates to a processing method of dendrobium officinale flower tea. The method comprises the following steps: (1) picking; (2) sorting and shaping; (3) brining; (4) washing; (5) airing; (6) baking and shaping; (7) performing aroma extraction. According to the method, a tea leaf drink capable of being stored for a long time is produced from dendrobium officinale flowers, so that the requirements of people on the different seasons of the dendrobium officinale flowers can be met, the problems of oversupplying during the flowering season of the dendrobium officinale flowers and undersupplying during the non-flowering season of the dendrobium officinale flowers are solved, and the waste of the dendrobium officinale flowers caused by high yield during the flowering period is avoided; the dendrobium officinale flower tea produced by the method can guarantee the medicinal value of the fresh dendrobium officinale flowers, is capable of excellently nourishing yin, moistening the lung, nourishing the stomach, producing body fluid, improving vision and clearing heat after being drunk for a long term, has the effects of improving immunity and resisting ageing, and is good for respiratory diseases, diabetes, chronic hepatitis, chronic gastritis and the like.

The invention relates to an emission reduction dry-type culture method for producing nonreactive pork. The method uses pig feeds, which contain feedstuff additive premix, and active water agent to feed the pigs. An organic adhesive layer is laid inside a pig shed. The active water agent contains natural plant extract and bacillus subtilis, and is drunk by the pigs through a leak protection and filtering water device arranged inside the pig shed. The feedstuff additive premix contains NSP enzyme, micro-ecological agent, plant extract and acidifier. The method can prevent the pigs from having intestinal bacteria and viral diseases and respiratory diseases, and reduce the discharge of fecaluria and living water, harmful gas produced by pig fecaluria and stench, and through which prevents the breeding of flies. At the same time of producing nonreactive port, the method can reduce the pollution caused by excreta.

The invention belongs to the biotechnology application field, and relates to simultaneous detection and genotyping of infections of 16 respiratory viruses (including FluA, FluB, sH1N1, PIV1, PIV2, PIV3, RSVA, RSVB, HRV, HMPV, HBoV, CoV NL63, CoV OC43, CoV 229E, CoV HKU1 and Adv) of nasopharyngeal extract specimens of patients of respiratory-related diseases of all levels of disease prevention and control institutions and sentinel hospitals. Specifically, nucleotide sequences of representative strains of the 16 respiratory viruses are downloaded from NCBI; through literature review and multiple sequence alignment, pathogen relatively-conservative regions are determined, and multiplex specific primers are designed. Single-tube multiplex (18 stages) PCR detection is carried out for detecting the 16 respiratory virus conservative regions, and an entire reaction takes less than 2 hours. According to the invention, a defect that genotyping cannot be carried out with conventional single-tube multiplex fluorescent qualitative PCR detections can be overcome, and defects of complicated operations, long time, and high cost of conventional chip detection methods can be overcome. With the application provided by the invention, a novel idea is provided for respiratory virus genotyping technologies. With characteristics of high specificity, high sensitivity, and high speed, powerful technological support is provided for rapid and accurate screening and genotyping of the respiratory-disease-related viruses. The invention has important significance upon the researches of respiratory-tract patient infection pathogen spectrum of out nation, and upon molecular epidemiological investigations.

A sample collection apparatus which measures biological samples and can be used to provide the early detection of respiratory diseases, for example tuberculosis induced by the pathogen mycobacterium tuberculosis. The sample collection apparatus has a sample collection unit and a corresponding complementary reader unit. The collection unit collects a sample exhaled from the user through a collection vessel with an optical interrogation region. The sample is spread on the inside of the vessel over the interrogation region and subsequently analyzed. The test results are displayed via the reader unit.

The invention discloses a colloidal gold method detection test strip and a reagent kit for an IgG antibody of a respiratory disease and a preparation method of the reagent kit. The test strip determines the IgG antibody by using a principle of an immunocapture method; respiratory herpes viruses, adenoviruses, influenzaviruses and an IgG antibody of mycoplasma pneumoniae can be detected jointly by one operation; the operation process is simplified; the test strip is simple, convenient, rapid and accurate in detection, suitable for mass detection and applicable to primary screening and epidemiological survey; and a result is distinct and easy to distinguish.

This description relates to insight into the asthma management habits of a patient or a plurality of patients. The provided information includes records of rescue medication usage events, records of controller medication events, and overall evaluations of a patients disease management. Users of the application may include both patients who may use the information to monitor their own habits or providers who may use the information to monitor patients or improve a patient's existing medication regimen.

An inhaler device comprising a container for powdered medicament, an inhalation channel, a movable metering member, a depressible actuator and a multiple dosage preventing means for locking the depressible actuator after use such that the actuator is unlocked only upon inhalation. The inhaler device is useful in the treatment of respiratory diseases such as asthma. The multiple dosage preventing means of the device eliminates the risk of unintentional overdosing.

The present invention provides a pressurized metered dose inhaler (pMDI) system, comprising a transparent or partially transparent canister which permits a patient to view the amount of medicament remaining in the pMDI system. The system of the present also comprises a dose counter which counts a dose when a dose is dispensed. The present invention provides a pMDI system which is improved over those currently used for treating respiratory diseases.

The invention discloses a florfenicol compound composition and a preparation method thereof. The composition is composed of florfenicol, azithromycin, tylosin, propylene glycol, dimethyl formamide, alpha-pyrrolidone, anhydrous ethanol and polyvinylpyrrolidone (PVP). The preparation method of the composition comprises steps of: 1) adding dimethyl formamide to florfenicol, stirring and dissolving; and sequentially adding propylene glycol, alpha-pyrrolidone and anhydrous ethanol, and stirring to mix evenly; 2) adding azithromycin and tylosin, and stirring to mix evenly; 3) heating with stirring at 40 DEG C, adding polyethylene pyrrole pyrrolidone, dissolving and continuing to stir for 15min; and 4) filtering the obtained solution, inflating nitrogen and encapsulating to obtain the florfenicol compound composition. The compound composition provided by the invention is mainly used in the treatment of swine respiratory diseases, and especially has specific long-term treatment effect and no recurrence on respiratory diseases, such as infectious pleuropneumonia, Haemophilus parasuis, swine plague and asthma.

The invention relates to the composition of an ambroxol HCl-containing sustained-release pellet and a preparation method. The sustained-release pellet consists of two parts which are a quick-release pellet core and a sustained-release coating film respectively, can achieve the effect of long-term release approaching to zero-order release, is mainly used for treating acute and chronic respiratory diseases, and is a medicament of first choice for dispelling phlegm.